Myers Jeff Lynn
Known title: Chief Medical OfficerCIK: 0001971112
Associated companies
Transaction History
| XAIR | ▼ Sell | Open Market | 3,423 | $8K | 12/27/2023 | View on chart |
| XAIR | ▲ Buy | Grant | 50,000 | $0 | 3/27/2023 | View on chart |
| XAIR | ▼ Sell | Open Market | 3,423 | $8K | 12/27/2023 | View on chart |
| XAIR | ▲ Buy | Grant | 50,000 | $0 | 3/27/2023 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Beyond Air Affirms FY2027 Sales Guidance at $16‑18M
Beyond Air Inc. (XAIR) confirmed its FY2027 sales guidance at $16‑18 million, matching the $16.715 million estimate from analysts. The company also reported preliminary Q2 revenue of about $2.3 million and reiterated the same FY2026 revenue range of $16‑18 million. These updates suggest the firm is on track to meet its projected sales targets for the next few years.
Beyond Air Affirms FY2027 Sales Guidance at $16‑18M. Beyond Air Inc. (XAIR) confirmed its FY2027 sales guidance at $16‑18 million, matching the $16.715 million estimate from analysts. The company also reported preliminary Q2 revenue of about $2.3 million and reiterated the same FY2026 revenue range of $16‑18 million. These updates suggest the firm is on track to meet its projected sales targets for the next few years.